Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109541" target="_blank" >RIV/00843989:_____/22:E0109541 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/22:10448671 RIV/61988987:17110/22:A2302IVM

Result on the web

<a href="https://journals.viamedica.pl/rpor/article/view/RPOR.a2022.0003/66028" target="_blank" >https://journals.viamedica.pl/rpor/article/view/RPOR.a2022.0003/66028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5603/rpOr.a2022.0003" target="_blank" >10.5603/rpOr.a2022.0003</a>

Result language

angličtina

Original language name

Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up

Original language description

Background: This retrospective analysis evaluated the long-term outcome of spinal stereotactic body radiotherapy (SBRT) treatment for hemangioblastomas. Materials and methods: Between 2010 and 2018, 5 patients with 18 Von-Hippel Lindau-related pial-based spinal hemangioblastomas were treated with fractionated SBRT. After precisely registering images of all relevant datasets, we delineated the gross tumor volume, spinal cord (including intramedullary cysts and/or syrinxes), and past radiotherapy regions. A sequential optimization algorithm was used for dose determinations, and patients received 25–26 Gy in five fractions or 24 Gy in three fractions. On-line image guidance, based on spinal bone structures, and two orthogonal radiographs were provided. The actuarial nidus control, surgery-free survival, cyst/syrinx changes, and progression-free survival were calculated with the Kaplan-Meier method. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Results: The median follow-up was 5 years after SBRT. Patients displayed one nidus progression, one need of neurosurgery, and two cyst/syrinx progressions directly connected to symptom worsening. No SBRT-related complications or acute adverse radiation-related events occurred. However, one asymptomatic radiological sign of myelopathy occurred two years after SBRT. All tumors regressed; the one-year equivalent tumor volume reduction was 0.2 mL and the median volume significantly decreased by 28% (p = 0.012). Tumor volume reductions were not correlated with the mean (p = 0.19) or maximum (p = 0.16) dose. Conclusions: SBRT for pial-based spinal hemangioblastomas was an effective, safe, viable alternative to neurosurgery in asymptomatic patients. Escalating doses above the conventional dose-volume limits of spinal cord tolerance showed no additional benefit.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Reports of practical oncology and radiotherapy

ISSN

1507-1367

e-ISSN

2083-4640

Volume of the periodical

27

Issue of the periodical within the volume

1

Country of publishing house

PL - POLAND

Number of pages

8

Pages from-to

134-141

UT code for WoS article

000861833600001

EID of the result in the Scopus database

2-s2.0-85126917567